ZLAB Zai Lab Limited Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

ZLAB [NASD]

Zai Lab Limited

Healthcare | Biotechnology | China

statements

Index	-	P/E	-	EPS (ttm)	-3.03	Insider Own	7.64%	Shs Outstand	67.35M	Perf Week	7.24%
Market Cap	6.68B	Forward P/E	-	EPS next Y	-2.69	Insider Trans	0.00%	Shs Float	40.65M	Perf Month	19.76%
Income	-195.10M	PEG	-	EPS next Q	-1.03	Inst Own	65.60%	Short Float	6.77%	Perf Quarter	45.14%
Sales	13.00M	P/S	513.99	EPS this Y	-14.60%	Inst Trans	0.39%	Short Ratio	6.04	Perf Half Y	113.42%
Book/sh	4.38	P/B	19.86	EPS next Y	13.20%	ROA	-	Target Price	82.44	Perf Year	143.07%
Cash/sh	3.59	P/C	24.22	EPS next 5Y	-	ROE	-	52W Range	29.43 - 89.48	Perf YTD	109.11%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-67.50%	52W High	-2.77%	Beta	-
Dividend %	-	Quick Ratio	6.10	Sales past 5Y	-	Gross Margin	71.10%	52W Low	195.62%	ATR	3.99
Employees	692	Current Ratio	6.30	Sales Q/Q	3501.00%	Oper. Margin	-	RSI (14)	63.94	Volatility	4.64% 5.05%
Optionable	Yes	Debt/Eq	0.02	EPS Q/Q	-396.50%	Profit Margin	-	Rel Volume	0.45	Prev Close	86.97
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	455.41K	Price	87.00
Recom	1.60	SMA20	8.91%	SMA50	18.75%	SMA200	64.52%	Volume	10,805	Change	0.03%

Apr-28-20

Initiated

Goldman

Buy

Apr-15-20

Initiated

Guggenheim

Buy

$75

Jul-12-19

Initiated

BofA/Merrill

Buy

Jul-05-19

Initiated

Macquarie

Outperform

Jan-29-19

Initiated

Credit Suisse

Outperform

Nov-21-18

Initiated

Jefferies

Buy

Jun-21-18

Resumed

Leerink Partners

Outperform

$43

Feb-14-18

Upgrade

JP Morgan

Neutral → Overweight

Oct-16-17

Initiated

Leerink Partners

Outperform

$42

Oct-16-17

Initiated

JP Morgan

Neutral

$32

Jul-07-20 11:37PM	Turning Point Therapeutics and Zai Lab Announce Exclusive License Agreement for Repotrectinib in Greater China PR Newswire
07:30AM	Turning Point Therapeutics and Zai Lab Announce Exclusive License Agreement For Repotrectinib in Greater China GlobeNewswire
Jun-17-20 02:03PM	Do Hedge Funds Love Zai Lab Limited (ZLAB)? Insider Monkey
May-28-20 07:05PM	Zai Lab Announces Positive Topline Results from the NORA Phase 3 Study of ZEJULA® as Maintenance Therapy for Chinese Patients with Platinum-sensitive, Recurrent Ovarian Cancer PR Newswire
07:37AM	Zai Lab Announces Positive Topline Results from the NORA Phase 3 Study of ZEJULA® as Maintenance Therapy for Chinese Patients with Platinum-sensitive, Recurrent Ovarian Cancer GlobeNewswire
May-27-20 07:30AM	Zai Lab Announces Presentations at June Conferences GlobeNewswire
May-18-20 09:45PM	Zai Lab Announces First Chinese Patient Dosed in the Global Phase 3 ATTACK Trial of Sulbactam- Durlobactam for Patients with Carbapenem-Resistant Acinetobacter Infections PR Newswire
07:30AM	Zai Lab Announces First Chinese Patient Dosed in the Global Phase 3 ATTACK Trial of Sulbactam-Durlobactam for Patients with Carbapenem-Resistant Acinetobacter Infections GlobeNewswire
May-13-20 10:10AM	China NMPA Approves Optune® for the Treatment of Newly Diagnosed and Recurrent Glioblastoma Business Wire
May-11-20 11:14AM	Optimism Runs High for MacroGenics GuruFocus.com +6.06%
May-08-20 01:18PM	The Top 5 Buys of the Matthews Asia Small Companies Fund GuruFocus.com
May-06-20 07:30AM	Zai Lab Announces NDA for Omadacycline Granted Priority Review by Chinas NMPA GlobeNewswire
Apr-30-20 07:30AM	Zai Lab Announces Upcoming Participation in the BofA Securities 2020 Health Care Conference GlobeNewswire
Apr-16-20 07:30AM	Zai Lab Announces Chinas NMPA Grants Priority Review to the sNDA for ZEJULA (Niraparib) for First-Line Ovarian Cancer Maintenance Treatment GlobeNewswire
Apr-08-20 06:00AM	Regeneron and Zai Lab Announce Regional Strategic Collaboration for REGN1979 (CD20xCD3 Bispecific Antibody) GlobeNewswire +7.30%
Mar-28-20 09:09PM	Hedge Funds Have Never Been This Bullish On Zai Lab Limited (ZLAB) Insider Monkey
Mar-19-20 12:21PM	Zai Lab Announces Financial Results for Full Year Ended December 31, 2019 and Corporate Updates PR Newswire
11:30AM	Is Zai Lab Limited Unsponsored (ZLAB) Outperforming Other Medical Stocks This Year? Zacks
07:30AM	Zai Lab Announces Financial Results for Full Year Ended December 31, 2019 and Corporate Updates GlobeNewswire
06:30AM	Zai Lab Ltd. to Host Earnings Call ACCESSWIRE
Mar-16-20 07:30AM	Zai Lab Announces Acceptance of sNDA Submission of ZEJULA® (Niraparib) for First-Line Maintenance Treatment of Ovarian Cancer in China by the NMPA GlobeNewswire -13.82%
Mar-05-20 07:30AM	Zai Lab to Announce Financial Results for the Full Year Ended December 31, 2019 and Corporate Updates on March 19, 2020 GlobeNewswire
Feb-11-20 07:30AM	Zai Lab Announces Upcoming Participation at February Conferences GlobeNewswire
07:23AM	The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology Benzinga
06:47AM	Will Zai Lab Continue to Surge Higher? Zacks
Feb-10-20 07:30AM	Zai Lab Announces Acceptance of NDA Submission of Omadacycline in China by the NMPA GlobeNewswire +5.01%
Feb-04-20 07:30AM	Zai Lab Announces First Patients Treated in Separate Phase 1b and Registrational Bridging Studies GlobeNewswire
Jan-27-20 04:30PM	Zai Lab Announces Closing of Public Offering of American Depositary Shares and Full Exercise of Greenshoe Option GlobeNewswire
Jan-22-20 09:43PM	Zai Lab Announces Pricing of Public Offering of American Depositary Shares GlobeNewswire -7.02%
Jan-21-20 04:34PM	Zai Lab Announces Proposed Public Offering of American Depositary Shares GlobeNewswire
Jan-14-20 07:30AM	Zai Lab Appoints Lonnie Moulder to Board of Directors GlobeNewswire +10.62%
Jan-09-20 07:30AM	Zai Lab and Novocure Announce First Patient Enrolled in a Phase 2 Pilot Trial of Tumor Treating Fields Together with Chemotherapy as First-Line Treatment of Gastric Cancer GlobeNewswire
Dec-30-19 06:55AM	How Does Zai Lab Limited (NASDAQ:ZLAB) Affect Your Portfolio Volatility? Simply Wall St.
Dec-27-19 08:46AM	Benzinga Pro's Top 5 Stocks To Watch For Fri., Dec. 27, 2019: NKE, AXE, PT, FLXN, ZLAB Benzinga +5.28%
07:41AM	Zai Lab Announces NMPA Approval of ZEJULA® (Niraparib) in China as Maintenance Therapy for Patients with Recurrent Ovarian Cancer GlobeNewswire
Dec-23-19 07:30AM	Zai Lab Announces Upcoming Presentation at 38th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-16-19 07:30AM	Zai Lab Announces the Appointment of Timothy Yap, M.D., Ph.D., to its Scientific Advisory Board GlobeNewswire -6.04%
Dec-08-19 06:26PM	Hedge Funds Have Never Been This Bullish On Zai Lab Limited (ZLAB) Insider Monkey
Oct-30-19 07:30AM	Zai Lab Announces Upcoming Presentations at November Conferences GlobeNewswire
Oct-27-19 04:16PM	Heres What Hedge Funds Think About Zai Lab Limited (ZLAB) Insider Monkey
Oct-25-19 08:30AM	Zai Lab Partner, MacroGenics, Announces Initiation of Phase 2/3 MAHOGANY Study of Margetuximab in Gastric or Gastroesophageal Junction Cancer GlobeNewswire +5.22%
Oct-24-19 08:30AM	Zai Lab Partner, GSK, Announces U.S. Food and Drug Administration Approval of Additional Indication for Zejula (niraparib) for Late-line Treatment for Women with Recurrent Ovarian Cancer GlobeNewswire
Oct-04-19 07:30AM	Dr. Samantha Du, Zai Lab Founder and CEO, to Participate in Forbes Global CEO Conference GlobeNewswire
Sep-29-19 02:15PM	Phase 3 PRIMA trial of Zejula® (niraparib) is the first study to show a PARP inhibitor significantly improves PFS, regardless of biomarker status, when given as monotherapy in women with first-line platinum responsive advanced ovarian cancer GlobeNewswire
Sep-11-19 12:22PM	Should Zai Lab (NASDAQ:ZLAB) Be Disappointed With Their 93% Profit? Simply Wall St.
Sep-03-19 06:01PM	Zai Lab Limited (ZLAB) Q2 2019 Earnings Call Transcript Motley Fool
07:32AM	Zai Lab Announces Financial Results and Corporate Update for the Six Months Ended June 30, 2019 GlobeNewswire
06:30AM	Zai Lab Ltd. to Host Earnings Call ACCESSWIRE
Aug-27-19 07:30AM	Zai Lab Announces Publication of Pharmacokinetic Study of Niraparib in Chinese Ovarian Cancer Patients GlobeNewswire -7.42%
Aug-26-19 07:30AM	Zai Lab Announces Upcoming Presentations at September Conferences GlobeNewswire
Aug-20-19 07:30AM	Zai Lab to Report Financial Results for the Six Months Ended June 30, 2019 and Provide Corporate Update on September 3, 2019 GlobeNewswire
Aug-12-19 07:30AM	China National Medical Products Administration Grants Innovative Medical Device Designation for Optune® in China GlobeNewswire
07:30AM	China National Medical Products Administration Grants Innovative Medical Device Designation for Optune® in China Business Wire
Jul-05-19 04:01PM	Here is What Hedge Funds Think About Zai Lab Limited (ZLAB) Insider Monkey
Jul-02-19 07:42AM	Incyte enters license pact with Zai Lab to commercialize its cancer treatment in Greater China MarketWatch
07:30AM	Incyte and Zai Lab Announce Collaboration and License Agreement for INCMGA0012 in Greater China GlobeNewswire
07:30AM	Incyte and Zai Lab Announce Collaboration and License Agreement for INCMGA0012 in Greater China Business Wire
Jun-24-19 05:00AM	China biotech groups spend billions on overseas drug candidates Financial Times
Jun-12-19 09:23AM	Zai Lab Announces Approval to Commercialize ZEJULA (Niraparib) in Macau for Patients with Relapsed Ovarian Cancer GlobeNewswire
Jun-11-19 08:09AM	Do Insiders Own Lots Of Shares In Zai Lab Limited (NASDAQ:ZLAB)? Simply Wall St.
07:00AM	Deciphera Pharmaceuticals, Inc. and Zai Lab Limited Announce an Exclusive License Agreement for Ripretinib in Greater China GlobeNewswire
07:00AM	Deciphera Pharmaceuticals, Inc. and Zai Lab Limited Announce an Exclusive License Agreement for Ripretinib in Greater China Business Wire
Jun-03-19 07:30AM	Zai Lab Appoints Valeria Fantin, Ph.D., as Chief Scientific Officer GlobeNewswire
May-29-19 07:30AM	Zai Lab Announces Presentations at June Conferences GlobeNewswire
May-16-19 07:30AM	Zai Lab Announces CTA Approval to Initiate a Phase 3 Clinical Trial of ETX2514SUL for the Treatment of Carbapenem-Resistant Acinetobacter Infections GlobeNewswire
May-09-19 07:30AM	Zai Lab Announces Participation at Upcoming May Conferences GlobeNewswire
May-03-19 08:29PM	Heres What Hedge Funds Think About Zai Lab Limited (ZLAB) Insider Monkey
May-02-19 07:18PM	Zai Lab Announces Pricing of Public Offering of American Depositary Shares GlobeNewswire
May-01-19 05:00PM	3 Top Chinese Stocks to Watch in May Motley Fool
04:05PM	Zai Lab Announces Proposed Public Offering of American Depositary Shares GlobeNewswire
Apr-17-19 07:30AM	Zai Lab to Host Analyst & Investor Day on April 30, 2019 GlobeNewswire
Mar-30-19 10:06AM	Did Zai Lab's (NASDAQ:ZLAB) Share Price Deserve to Gain 38%? Simply Wall St.
Mar-12-19 07:30AM	Zai Lab Announces Presentations at March Conferences GlobeNewswire
Mar-07-19 07:30AM	Zai Lab Announces Financial Results and Corporate Update for Full Year 2018 GlobeNewswire
Feb-27-19 12:06AM	Macrogenics Inc (MGNX) Q4 2018 Earnings Conference Call Transcript Motley Fool
Feb-21-19 07:30AM	Zai Lab to Announce Full Year 2018 Financial Results GlobeNewswire
Feb-20-19 07:30AM	Zai Lab to Present at the 8th Annual SVB Leerink Global Healthcare Conference GlobeNewswire
Feb-07-19 08:08AM	The Daily Biotech Pulse: Galapagos-Evotec Forge Fibrosis Partnership, Sanofi Earnings, Alector To Debut Benzinga
Feb-06-19 06:16PM	MacroGenics stock spikes from positive results of cancer drug trial American City Business Journals +14.40%
Feb-01-19 09:06AM	Zacks.com featured expert Kevin Matras highlights: Meet, Zai Lab, NanoString Technologies, OSI Systems and AudioEye Zacks
07:30AM	Zai Lab Announces the Appointment of Immuno-Oncology Pioneer, Lieping Chen, M.D., Ph.D., to its Scientific Advisory Board GlobeNewswire
Jan-31-19 08:43AM	5 Stocks With Recent Price Strength to Enhance Your Return Zacks
Jan-28-19 07:30AM	Priority Review Granted to Zai Labs NDA Application for ZEJULA (Niraparib) in China GlobeNewswire
Jan-23-19 08:19AM	Moving Average Crossover Alert: Zai Lab Limited Zacks
06:08AM	Will Zai Lab Continue to Surge Higher? Zacks
Jan-15-19 05:08PM	Peninsula biotech sheds 20% of jobs to focus on drugs closer to finish line American City Business Journals +7.25%
Jan-09-19 07:30AM	Zai Lab Completes Enrollment of China Pivotal Trial of Niraparib as Second-Line Maintenance Therapy for Ovarian Cancer in China GlobeNewswire
Dec-28-18 07:30AM	Zai Lab Announces Launch of Optune® in Hong Kong for Patients with Glioblastoma Multiforme GlobeNewswire
Dec-19-18 07:30AM	Zai Lab to Present at the 37th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-16-18 10:05AM	Zai Lab Limited (ZLAB): Are Hedge Funds Right About This Stock? Insider Monkey
Dec-12-18 07:30AM	Zai Lab Announces Acceptance of NDA Submission of ZEJULA (Niraparib) in Mainland China by the NMPA GlobeNewswire +5.27%
Dec-03-18 09:00AM	George Soros Bought These 2 Healthcare Stocks in the Third Quarter Motley Fool
Nov-29-18 07:30AM	MacroGenics and Zai Lab Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Margetuximab, MGD013 and TRIDENT Molecule in Greater China GlobeNewswire
Nov-14-18 07:30AM	Zai Lab and Novocure Awarded Deal of the Year GlobeNewswire
Nov-07-18 07:30AM	Zai Lab Limited Announces Presentations at November Conferences GlobeNewswire +6.27%
Oct-22-18 07:30AM	Zai Lab Announces Approval of ZEJULA® (Niraparib) for Patients with Relapsed Ovarian Cancer in Hong Kong GlobeNewswire
Oct-01-18 08:00AM	Five Prime Therapeutics and Zai Lab Dosed First Patient in Phase 3, Global Registrational Trial of Bemarituzumab in Front-Line Advanced Gastric and Gastroesophageal Junction Cancers Business Wire
Sep-27-18 07:30AM	Zai Lab Appoints Industry Leader Tao Fu as President & Chief Operating Officer, Expands US Presence GlobeNewswire
Sep-26-18 07:30AM	Zai Lab Presents Results of its Pharmacokinetics (PK) Study for ZL-2306 (niraparib) in Chinese Ovarian Cancer Patients Showing Comparable Profile to non-Chinese Patients at the 21st Annual Meeting of the Chinese Society of Clinical Oncology GlobeNewswire
07:30AM	Zai Lab Presents Interim Results of its ongoing Phase 2 study of ZL-2301 (brivanib) in Chinese Patients with Advanced Hepatocellular Carcinoma (HCC) at the 21st Annual Meeting of the Chinese Society of Clinical Oncology GlobeNewswire

Zai Lab Limited, a biopharmaceutical company, engages in discovering or licensing, developing, and commercializing proprietary therapeutics that address medical needs in the fields of oncology, autoimmune, and infectious diseases in China. The company offers Niraparib, an oral small molecule poly ADP ribose polymerase 1/2 inhibitor for the treatment of multiple solid tumors, including ovarian and other types of lung cancer; and Optune, a cancer therapy for the treatment of glioblastoma multiforme. It also develops Ripretinib, a switch control inhibitor for the treatment of KIT and/or PDGFRa-driven cancers, including gastrointestinal stromal tumors, systemic mastocytosis, and other cancers; REGN1979 for the treatment of diffuse large B-cell lymphoma and follicular lymphoma; Margetuximab an immune-optimized anti-HER2 monoclonal antibody for the treatment of breast and gastric cancers; and INCMGA0012, an investigational monoclonal antibody for the treatment of MSI-high endometrial cancer. In addition, the company develops Bemarituzumab, a humanized monoclonal antibody for the treatment of gastric and gastroesophageal cancers; Omadacycline, an antibiotic to treat acute bacterial skin and skin structure, and community-acquired bacterial pneumonia infections; and Durlobactam for the treatment of acinetobacter baumannii bacterial infections. Zai Lab Limited has license and collaboration agreements with the TESARO Inc.; Paratek Bermuda, Ltd.; Five Prime Therapeutics, Inc.; Entasis Therapeutics Holdings, Inc.; Crescendo Biologics Ltd.; Novocure Limited; MacroGenics Inc.; Deciphera Pharmaceuticals, LLC; and Incyte Corporation. The company was founded in 2013 and is headquartered in Shanghai, China.

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience